Search Results

ZEUS Study of Uncertain DES Candidates Presented

March 31, 2014—Medtronic, Inc. (Minneapolis, MN) announced that findings from the ZEUS study of the company’s Endeavor Sprint zotarolimus-eluting stent (ZES) in uncertain drug-eluting stent (DES) candidates were presented by ZEUS lead investigator Marco Valgimigli, MD, at ACC.14, the 63rd annual scientific session of the American College of Cardiology, held in Washington, DC.

MATRIX Supports The Medicines Company's Bivalirudin in High-Risk PCI Patients

September 1, 2015—The Medicines Company announced that results from the antithrombin program of the MATRIX trial were presented during a Hot Line session of the European Society of Cardiology’s ESC Congress 2015 and published by Marco Valgimigli, MD, et al online ahead of print in The New England Journal of Medicine (NEJM).

Bivalirudin Shows Mixed Results in Antithrombin Evaluation of MATRIX

March 16, 2015—Results from the antithrombin program of the MATRIX study of minimizing adverse hemorrhagic events by transradial access site and systemic implementation of bivalirudin (Angiox, The Medicines Company) were presented at the American College of Cardiology’s 64th annual scientific session in San Diego, California.

ESC Focused Update on DAPT in Coronary Artery Disease Published

September 5, 2017—The European Society of Cardiology (ESC) announced that the first ESC focused update on dual antiplatelet therapy (DAPT) in coronary artery disease was published online in European Heart Journal and on the ESC website.

Published ZEUS Findings Support Medtronic's Endeavor Sprint ZES in Uncertain DES Candidates

March 2, 2015—Investigators in the ZEUS study concluded that using the Endeavor Sprint stent (Medtronic plc) combined with an abbreviated, tailored dual-antiplatelet therapy (DAPT) regimen resulted in a lower risk of 1-year major adverse cardiovascular events in uncertain candidates for drug-eluting stent (DES) implantation compared to treatment with a bare-metal stent using a similar duration of DAPT.

Interim Data Reported From the First-in-Human MOCA I Trial of CorFlow's CoFI System

June 29, 2020—Switzerland-based CorFlow Therapeutics AG announced that Felice Gragnano, MD, presented interim clinical data from the MOCA I phase 2 clinical trial during the virtual PCR eCourse 2020.

MATRIX Shows Transradial Access Should Be Preferred for Most Catheter-Based Coronary Interventions

March 16, 2015—Results from the access-site program of the MATRIX study of minimizing adverse hemorrhagic events by transradial access site and systemic implementation of bivalirudin (Angiox, The Medicines Company) demonstrated that patients with acute coronary syndrome (ACS) undergoing coronary angiography had a significantly lower risk of major bleeding and death if the procedure was conducted by transradial access rather transfemoral access.

Vesalio’s NATURE Study of enVast Coronary Thrombectomy System Commences Enrollment

January 6, 2022–Vesalio recently announced enrollment commencement for the randomized, multicenter NATURE clinical study of the company’s enVast thrombectomy system for patients with ST-segment elevation myocardial infarction (STEMI) who are undergoing percutaneous coronary intervention.

Medicure Completes Enrollment in FABOLUS-FASTER Trial of Aggrastat in Patients Undergoing PCI

December 12, 2019—Medicure Inc. announced the completion of the FABOLUS-FASTER phase 4 trial of Aggrastat (tirofiban hydrochloride) injection versus Kengreal (cangrelor; The Medicines Company) in patients undergoing percutaneous coronary intervention (PCI).

PRODIGY Questions 2-Year Duration of Dual-Antiplatelet Therapy After Stenting

August 30, 2011—The European Society of Cardiology (ESC) announced that 24-month data from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study) study were presented at its annual meeting in Paris, France.

Biotronik’s Orsiro Mission DES With Short DAPT Studied in BIOFLOW-DAPT

August 30, 2023—Biotronik announced that 1-year data from the BIOFLOW-DAPT study demonstrated noninferiority and a good safety profile for the company’s Orsiro Mission drug-eluting stent (DES) compared with the Resolute Onyx DES (Medtronic) in patients at high risk of bleeding receiving short dual antiplatelet therapy (DAPT) percutaneous coronary intervention (PCI).

CorFlow’s CoFI System Evaluated in MOCA I First-in-Human Study for Detecting Microvascular Obstruction

May 19, 2023—CorFlow Therapeutics AG, a Switzerland-based developer of the CoFI controlled flow infusion system for diagnostic assessment and therapy delivery for coronary microvascular obstruction (MVO), announced the positive interim results of its MOCA I study.

Abbott Vascular's XIENCE 28 GLOBAL Trial Enrolls First Patient in Europe

February 12, 2018—Abbott Vascular announced the first patient has been enrolled in XIENCE 28 GLOBAL, a clinical trial evaluating whether patients at high risk of bleeding can safely remain on dual antiplatelet therapy (DAPT) for only 28 days after implantation with a Xience everolimus-eluting coronary stent.

First Patient Enrolled in Biotronik's BIOFLOW-DAPT Trial

May 6, 2020—Biotronik announced the enrollment of the first patient in the BIOFLOW-DAPT trial evaluating a dual-antiplatelet therapy (DAPT) regimen in a complex subgroup of patients undergoing percutaneous coronary intervention (PCI).

CorFlow Advances MOCA II, Launches REVITALISE Trial

May 18, 2026—CorFlow Therapeutics AG, a Switzerland-based company focused on cardiac care targeting microvascular disease, announced milestones in its MOCA II FDA pivotal trial and REVITALISE trial of the CorFlow continuous flow infusion (CoFI) system, which outputs a novel pressure parameter—PCoFI—for the detection of microvascular obstruction (MVO).

CorFlow’s MOCA-II Pivotal Trial Receives FDA IDE Approval

July 10, 2025—CorFlow Therapeutics AG, a Switzerland-based company focusing on cardiac care targeting microvascular disease, recently announced that the FDA has approved an investigational device exemption (IDE) for the CorFlow CoFl system, allowing for commencement of the MOCA-II United States pivotal clinical trial of the technology.

Miracor Medical’s PiCSO Pivotal Study Receives FDA IDE Approval

August 30, 2022—Miracor Medical SA, which is based in Awans, Belgium, recently announced FDA approval of an investigational device exemption (IDE) that will allow the company to initiate the pivotal PiCSO-AMI-II study of PiCSO, its pressure-controlled intermittent coronary sinus occlusion technology.

1-Month DAPT Approved in Europe for Abbott’s Xience Stent in Patients at High Bleeding Risk

April 6, 2021—Abbott announced its Xience stent has received CE Mark approval in Europe for shorter duration of dual antiplatelet therapy (DAPT) for patients at high bleeding risk (HBR).